Drugs / PNT2258
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02378038 | Aug 2015 → Jun 2016 | Richter transformation | Sierra Oncology LLC - a GSK company | Terminated | No outcome recorded |
| Phase 2 | NCT02226965 | Dec 2014 → Jul 2016 | diffuse large B-cell lymphoma | Sierra Oncology LLC - a GSK company | Completed | No outcome recorded |
| Phase 2 | NCT01733238 | Nov 2012 → Aug 2016 | non-Hodgkin lymphoma | Sierra Oncology LLC - a GSK company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PNT2258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02226965 ↗ |
| Action | Inhibit | “the oligonucleotide would promote anticancer activity via suppression of BCL2 transcription” PMID 34417162 ↗ Jul 2021 |
| Modality | Oligonucleotide (other) | “PNT2258 consists of a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the BCL2 gene” PMID 34417162 ↗ Jul 2021 |
| Route | Intravenous | “received intravenous PNT2258 120 mg/m2” PMID 34417162 ↗ Jul 2021 |
| Target | BCL2 | “designed to target the regulatory region upstream of the BCL2 gene” PMID 34417162 ↗ Jul 2021 |